Neurocrine Biosciences Inc (NASDAQ: NBIX), a neuroscience-focused, biopharmaceutical company, announced on Tuesday, that it has reported its financial results for the fourth quarter of 2019.
The company reported GAAP net income and diluted earnings per share of USD34m and USD0.35 respectively in the fourth quarter of 2019, compared to USD18m and USD0.19 respectively in the same period in 2018.
The firm posted non-GAAP net income and diluted earnings per share at USD102m and USD1.05 respectively in the fourth quarter of 2019, as against USD38m and USD0.40 for the same period in 2018.
Eli Lilly announces Q1 2026 dividend
Amgen announces Q4 2025 dividend
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Thermo Fisher Scientific to acquire Clario Holdings, expanding clinical data capabilities
Nanoform and Revio Therapeutics partner to develop long-acting hydrogel therapy for glioma
Cumberland Pharmaceuticals adds FDA-approved oral capsule for H. pylori to commercial portfolio
IP Group positions for future royalties following Pfizer's USD7.3bn acquisition of Metsera
AstraZeneca strikes landmark drug pricing deal with US Government